Taiwan FDA sees 'difficulties' with UBI Asia's new EUA review request

Taiwan's Food and Drug Administration (FDA) has voiced its doubts over a bid by Taiwan-based United Biomedical Inc. (UBI) Asia to reapply for emergency use authorization (EUA) for its COVID-19 vaccine.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)